EU project aims to establish optimal therapy for blood cancer
Acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL) are among the most common forms of blood cancer in adults. Depending on the stage of the disease, patients receive chemotherapy, immunotherapy or a stem cell transplant. The so-called measurable residual disease (MRD) can be used to determine whether the leukaemia is responding very well to the therapy early on in the course of treatment.